Kestra Medical Technologies (NASDAQ:KMTS) CFO Vaseem Mahboob Sells 3,980 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 3,980 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $22.75, for a total value of $90,545.00. Following the completion of the sale, the chief financial officer directly owned 108,099 shares of the company’s stock, valued at approximately $2,459,252.25. This trade represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37.

Kestra Medical Technologies Trading Up 5.1%

KMTS opened at $23.99 on Tuesday. The firm’s fifty day moving average is $22.62 and its two-hundred day moving average is $22.48. The firm has a market cap of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million during the quarter. Equities research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on KMTS. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. BTIG Research boosted their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Finally, Oppenheimer started coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Kestra Medical Technologies presently has a consensus rating of “Hold” and a consensus target price of $27.83.

Hedge Funds Weigh In On Kestra Medical Technologies

Several hedge funds have recently modified their holdings of KMTS. Seven Grand Managers LLC bought a new position in Kestra Medical Technologies in the fourth quarter valued at approximately $2,652,000. Eventide Asset Management LLC raised its stake in shares of Kestra Medical Technologies by 5.4% during the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after purchasing an additional 65,288 shares in the last quarter. Summit Partners Public Asset Management LLC acquired a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at approximately $9,282,000. UBS Group AG boosted its holdings in shares of Kestra Medical Technologies by 34.9% in the 4th quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after buying an additional 69,908 shares during the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Kestra Medical Technologies by 15.0% in the fourth quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock valued at $5,817,000 after buying an additional 28,573 shares in the last quarter.

Key Stories Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.